Highbridge Capital Management (ASBP) discloses warrant-based Aspire Biopharma stake in 13G/A

Rhea-AI Filing Summary

Highbridge Capital Management, LLC filed Amendment No. 1 reporting beneficial ownership of Aspire Biopharma Holdings, Inc. common stock issuable upon exercise of warrants held by its advised funds. Highbridge reports 78 shares of common stock with sole voting and dispositive power, representing 0.0% of the class based on 1,295,234 shares outstanding as of May 13, 2026. The position is held on behalf of certain Highbridge funds, and overall ownership is disclosed as 5 percent or less of the class.

Key Figures

Shares beneficially owned: 78 shares Percent of class: 0.0% Shares outstanding: 1,295,234 shares +2 more

5 metrics

Shares beneficially owned 78 shares Common Stock issuable upon exercise of warrants held by Highbridge Funds

Percent of class 0.0% Beneficial ownership percentage of Aspire Biopharma common stock

Shares outstanding 1,295,234 shares Common stock outstanding as of May 13, 2026, per issuer’s Form 10-Q

Sole voting power 78.00 shares Number of shares over which Highbridge has sole voting power

Sole dispositive power 78.00 shares Number of shares over which Highbridge has sole dispositive power

Key Terms

beneficial owner, Sole Voting Power, Sole Dispositive Power, Ownership of 5 Percent or Less of a Class, +1 more

5 terms

beneficial owner regulatory

"should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Sole Voting Power financial

"5 | Sole Voting Power 78.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"7 | Sole Dispositive Power 78.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Ownership of 5 Percent or Less of a Class regulatory

"Item 5. | Ownership of 5 Percent or Less of a Class. | Ownership of 5 percent or less of a class"

CUSIP No. financial

"(e) | CUSIP No.: 738920305"

FAQ

What stake in Aspire Biopharma Holdings, Inc. (ASBP) does Highbridge report in this Schedule 13G/A?

Highbridge reports beneficial ownership of 78 shares of Aspire Biopharma common stock issuable upon exercise of warrants. This represents 0.0% of the outstanding 1,295,234 shares as of May 13, 2026, indicating a very small position.

How is Highbridge’s ownership in ASBP held according to the Schedule 13G/A?

The ownership relates to shares issuable upon exercise of warrants held by certain funds and accounts advised by Highbridge. The Highbridge Funds have the right to receive dividends or proceeds from sale of the reported shares of common stock.

What voting and dispositive powers over ASBP shares does Highbridge report?

Highbridge reports sole voting power over 78 shares and sole dispositive power over 78 shares of Aspire Biopharma common stock. It reports no shared voting or shared dispositive power over any shares in this filing.

What class of securities of ASBP is covered and what is the CUSIP?

The filing covers Aspire Biopharma’s common stock, par value $0.0001 per share. The class is identified with CUSIP 738920305, and the reported holdings are issuable upon exercise of warrants held by the Highbridge Funds.

Does Highbridge own more than 5% of Aspire Biopharma (ASBP) in this Schedule 13G/A?

No. Highbridge reports ownership of 5 percent or less of Aspire Biopharma’s common stock. The percentage of class shown is 0.0%, based on 1,295,234 shares outstanding and assuming exercise of the warrants held.

Who signed the Schedule 13G/A for Highbridge regarding ASBP?

The report was signed by Kirk Rule, Executive Director, on behalf of Highbridge Capital Management, LLC. The signature is presented as /s/ Kirk Rule with the title Executive Director and a date of August 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 12:31 PM Accepted by SEC EDGAR 08/14/2026 - 12:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Aspire Biopharma Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

738920305

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 738920305

1

Names of Reporting Persons

Highbridge Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 78.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 78.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

78.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Reflects shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aspire Biopharma Holdings, Inc.
(b)	Address of issuer's principal executive offices: 23150 Fashion Drive, Suite 230, Estero, Florida 33928
Item 2.
(a)	Name of person filing: This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the common stock, par value $0.0001 per share ("Common Stock") of Aspire Biopharma Holdings, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds; The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
(c)	Citizenship: Highbridge is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 738920305
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 1,295,234 shares of Common Stock outstanding as of May 13, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 15, 2026, and assumes the exercise of the warrants held by the Highbridge Funds.
(b)	Percent of class: 0.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Highbridge Capital Management, LLC

Signature:	/s/ Kirk Rule
Name/Title:	By: Kirk Rule, Executive Director
Date:	08/14/2026